Nevro (NVRO) to Release Earnings on Wednesday

Nevro (NYSE:NVRO) is expected to post its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Nevro to post earnings of ($0.67) per share and revenue of $100.02 million for the quarter.

Nevro (NYSE:NVRO) last issued its earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.40. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The business had revenue of $96.60 million for the quarter, compared to analysts’ expectations of $93.09 million. During the same period in the previous year, the firm posted ($0.65) EPS. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, analysts expect Nevro to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nevro Price Performance

NYSE:NVRO opened at $5.72 on Wednesday. The stock has a 50 day moving average price of $4.32 and a 200 day moving average price of $5.12. The stock has a market cap of $214.33 million, a PE ratio of -3.03 and a beta of 0.91. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. Nevro has a one year low of $3.16 and a one year high of $17.75.

Wall Street Analyst Weigh In

NVRO has been the topic of several analyst reports. Truist Financial reduced their price target on Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Nevro in a report on Tuesday, November 12th. JMP Securities restated a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Robert W. Baird lifted their price target on shares of Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Tuesday, November 12th. Finally, Morgan Stanley lowered Nevro from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $9.00 to $4.00 in a research report on Monday, December 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.